Johansson-Percival A., B. He, and Ganss.2018. Immune-reprogramming of tumor vessels: it takes two to tango, Trends Immunology, 39, 801-814.
SELECTED PUBLICATIONS
He B., A. Jabouille, V. Steri, A. Johansson-Percival, I.P. Michael, V.R. Kotamraju, R. Junckerstorff, A.K. Nowak, J. Hamzah, G. Lee, G. Bergers and Ganss.2018. Vasuclar targeting by LIGHT normalizes blood vessels in primary brain cancer and induces intratumoral high endothelial venules. Journal of Pathology, 245: 209-221.
Johansson-Percival A., B. He, Z-J. Li, A. Kjellen, K. Russell, J. Li, I. Larma and Ganss.2017. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nature Immunology 11: 1207-27.
Johansson-Percival, A, Z-J. Li, Lakhiani, D.D., B. He, X. Wang, J. Hamzah and Ganss. Intratumoral LIGHT restores pericyte contractility and vessel integrity. 2015. Cell Reports, 13, 2687-2698.
Holobotovskyy V, Chong JS, Burchell J, He B, Phillips M, Leader L, Murphy TV, Sandow SL, McKitrick D , Charles A, Tare M, Arnolda L,Ganss R. Regulator of G protein signaling 5 is a determiant of gestational hypertension and preeclampsia. 2015. Science Translational Medicine 7, 290ra88. [Sci Transl Med]
Holobotovskyy V, Manzur M, Burchell J, Bolitho E, Tare M, Viola H, Hool L, Arnolda L, McKitrick D ,Ganss R. Regulator of G protein signaling 5 controls blood pressure homeostasis and vessel wall remodeling. 2013. Circulation Research 112 (5):781-91. [NCBI PubMed Entry]
Johansson A, Hamzah J, Payne CJ, Ganss R. 2012. Tumor-targeted TNFα Stabilizes Tumor Vessels and Enhances Active Immunotherapy. PNAS 109 (20):7841-6. [NCBI PubMed Entry]
Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, Arnold B, Ganss R. 2008. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453(7193):410-4. [NCBI PubMed Entry] [Nature Website]
Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hämmerling GJ,Ganss R. 2008. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. The Journal of Clinical Investigation 118(5):1691-9. [NCBI PubMed Entry]
Du R, Lu KV, Petritsch C, Liu P,Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G. 2008. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13(3):206-20. [NCBI PubMed Entry]
